Enochian Biosciences Inc. (NASDAQ:ENOB – Get Rating) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,500,000 shares, an increase of 5.6% from the February 13th total of 1,420,000 shares. Approximately 9.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 55,200 shares, the short-interest ratio is currently 27.2 days.
Institutional Investors Weigh In On Enochian Biosciences
Several institutional investors have recently modified their holdings of ENOB. Citigroup Inc. lifted its stake in shares of Enochian Biosciences by 202.3% in the 1st quarter. Citigroup Inc. now owns 29,871 shares of the company’s stock valued at $246,000 after purchasing an additional 19,991 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Enochian Biosciences by 4.7% in the 1st quarter. BlackRock Inc. now owns 200,086 shares of the company’s stock valued at $1,651,000 after purchasing an additional 9,059 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Enochian Biosciences in the 1st quarter valued at approximately $1,744,000. State Street Corp lifted its stake in shares of Enochian Biosciences by 7.9% in the 1st quarter. State Street Corp now owns 52,087 shares of the company’s stock valued at $430,000 after purchasing an additional 3,796 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Enochian Biosciences by 26.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 82,883 shares of the company’s stock valued at $684,000 after purchasing an additional 17,260 shares during the last quarter. 7.16% of the stock is owned by institutional investors.
Enochian Biosciences Price Performance
Shares of Enochian Biosciences stock opened at $1.12 on Friday. The stock has a 50 day moving average of $1.12 and a 200 day moving average of $1.54. Enochian Biosciences has a 12 month low of $0.90 and a 12 month high of $9.16. The firm has a market cap of $62.40 million, a PE ratio of -1.37 and a beta of 1.22. The company has a current ratio of 0.48, a quick ratio of 0.48 and a debt-to-equity ratio of 0.02.
Enochian Biosciences Company Profile
Enochian Biosciences, Inc is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.
- Get a free copy of the StockNews.com research report on Enochian Biosciences (ENOB)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.